2019 ASCCP Risk-Based Management Consensus Guidelines: Updates Through 2023
Rebecca B. Perkins, Richard S. Guido, Philip E. Castle, David Chelmow, Mark H. Einstein, Francisco García, Warner K. Huh, Jane J. Kim, Anna‐Barbara Moscicki, Ritu Nayar, Mona Saraiya, George F. Sawaya, Nicolas Wentzensen, Mark Schiffman
Abstract
ABSTRACT: This Research Letter summarizes all updates to the 2019 Guidelines through September 2023, including: endorsement of the 2021 Opportunistic Infections guidelines for HIV+ or immunosuppressed patients; clarification of use of human papillomavirus testing alone for patients undergoing observation for cervical intraepithelial neoplasia 2; revision of unsatisfactory cytology management; clarification that 2012 guidelines should be followed for patients aged 25 years and older screened with cytology only; management of patients for whom colposcopy was recommended but not completed; clarification that after treatment for cervical intraepithelial neoplasia 2+, 3 negative human papillomavirus tests or cotests at 6, 18, and 30 months are recommended before the patient can return to a 3-year testing interval; and clarification of postcolposcopy management of minimally abnormal results.